Immuno-Therapy in the Treatment of Cancer: Implications for Efficacy and Economic Evaluations
L'immunoterapia Nel Trattamento Del Cancro: Implicazioni Per Le Valutazioni Di Efficacia Ed Economiche
Keywords:Cancer immunotherapy, Clinical endpoints, Cost-effectiveness, Market access
AbstractIn the last few years, immuno-oncology has partially modified the paradigm of cancer treatment, due to the observation of long-term survivors among patients with advanced tumors and with a predicted limited life expectancy, if treated with immunotherapeutic agents. This paper illustrates the opinion of an expert panel (Scientific Board on Immuno-oncology and Cancer Treatment) regarding the clinical and economic assessments of immunologic anticancer treatments. The agreement on the document was reached through a Consensus Conference. Overall survival and/or survival rates at specific time-points are the ideal parameters to evaluate the efficacy and effectiveness of immunotherapies. Since benefits affect different patients at different times across cancer indications of immunotherapies, short-term (on most of targeted patients) and long-term effects on smaller groups should be considered. When market access decisions are taken, the benefit profile of immunotherapies has important implications for their economic assessment. Robust long-term extrapolation of expected survival rates should be carried out when cost-efficacy (effectiveness) of immunotherapies is estimated; mean instead of median incremental survival rate is a more appropriate measure; real-world data collection should be strengthened and used to eventually revise decisions taken on price and reimbursement.
How to Cite
Jommi C, Mennini FS, Canonico PL, Bruzzi P. Immuno-Therapy in the Treatment of Cancer: Implications for Efficacy and Economic Evaluations: L’immunoterapia Nel Trattamento Del Cancro: Implicazioni Per Le Valutazioni Di Efficacia Ed Economiche. Grhta [Internet]. 2016 Nov. 2 [cited 2023 Apr. 1];3(1):1-8. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/401
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.